TY - JOUR
T1 - Cytokine modified tumor vaccines
AU - Armstrong, Todd D.
AU - Jaffee, Elizabeth M.
PY - 2002/7
Y1 - 2002/7
N2 - The immune system can recognize tumors, but may be actively tolerized to tumors during the tumorigenesis process. The identity of most tumor antigens remains unknown, but the number is growing due to new techniques. Most clinical trials using genetically modified tumor vaccines have shown immunological responses (DTH), but few clinical responses. Certain chemotherapeutic agents may enhance the immune effects of genetically modified tumor vaccines.
AB - The immune system can recognize tumors, but may be actively tolerized to tumors during the tumorigenesis process. The identity of most tumor antigens remains unknown, but the number is growing due to new techniques. Most clinical trials using genetically modified tumor vaccines have shown immunological responses (DTH), but few clinical responses. Certain chemotherapeutic agents may enhance the immune effects of genetically modified tumor vaccines.
UR - http://www.scopus.com/inward/record.url?scp=0036660868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036660868&partnerID=8YFLogxK
U2 - 10.1016/S1055-3207(02)00020-0
DO - 10.1016/S1055-3207(02)00020-0
M3 - Review article
C2 - 12487062
AN - SCOPUS:0036660868
SN - 1055-3207
VL - 11
SP - 681
EP - 696
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
IS - 3
ER -